Update on New Antivirals Under Development for the Treatment of Double-Stranded

StephenW

Clinical Pharmacology & Therapeutics (2010) 88 5, 610–619. doi:10.1038/clpt.2010.178

        Update on New Antivirals Under Development for the Treatment of Double-Stranded DNA Virus Infections

L K Dropulic1 and J I Cohen1

1Medical Virology Section, Laboratory of Clinical Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA

Correspondence: JI Cohen, ([email protected])

Received 4 May 2010; Accepted 30 June 2010; Published online 29 September 2010.                       

Abstract

All the currently available antiviral agents used in the treatment of double-stranded (ds) DNA viruses, with the exception of interferon-α, inhibit the same target, the viral DNA polymerase. With increasing reports of the development of resistance of herpes simplex virus (HSV), cytomegalovirus (CMV), and hepatitis B virus (HBV) to some of these drugs, new antiviral agents are needed to treat these infections. Additionally, no drugs have been approved to treat several DNA virus infections, including those caused by adenovirus, smallpox, molluscum contagiosum, and BK virus. We report the status of 10 new antiviral drugs for the treatment of dsDNA viruses. CMX-001 has broad activity against dsDNA viruses; 3 helicase–primase inhibitors, maribavir, and FV-100 have activity against certain herpesviruses; ST-246 inhibits poxviruses; GS-9191 inhibits papillomaviruses; and clevudine and emtricitabine are active against HBV. Most of these drugs have completed at least phase I trials in humans, and many are in additional clinical trials.

From Google translate:

临床药理学与治疗学（2010）88 5，610-619。分类号：10.1038/clpt.2010.178
更新发展中的双链DNA病毒感染的抗病毒药物治疗新

L K Dropulic1和J I Cohen1

1Medical病毒科，临床传染病实验室，卫生部，贝塞斯达，马里兰州，美国国家研究院

通讯：纪科恩（[email protected]）

收到2010年5月4日，接受2010年6月30日，2010年9月29日在线发表。

摘要

当前所有可用抗病毒药物用于双链（DS）的DNA病毒治疗，干扰素-α异常，代理，抑制同一个目标，病毒DNA聚合酶。随着越来越多的单纯疱疹病毒性（单纯疱疹病毒）的发展报告，巨细胞病毒（CMV）和乙型肝炎病毒（HBV），对这些药物的一些新的抗病毒药物是需要治疗这些感染。此外，没有药物被批准用于治疗多种DNA病毒感染，包括腺病毒，天花，传染性软疣，和BK病毒引起的。我们报告的10个新的抗病毒药物治疗的双链DNA病毒的状态。的CMX - 001具有广阔的双链DNA病毒活性的3解旋酶，引物酶抑制剂，maribavir，和FV - 100具有对某些疱疹病毒活性; ST段- 246抑制痘病毒;广深高速- 9191抑制乳头状瘤病毒和克来夫定和恩曲他滨的抗HBV活性。由于这些药物大部分已完成第一阶段试验至少在人类中，和许多额外的临床试验阶段